Heidelberg Pharma AG (ETR:HPHA) | WebDisclosure

Basculer en Français

9475	Companies
185442	Keywords
117781	Articles
99296	Press releases

Home
Companies
Heidelberg Pharma AG

PRESS RELEASE

published on 04/24/2025 at 07:16, 7 months 11 days ago

Heidelberg Pharma AG: Interim Statement on the First Three Months of Financial Year 2025
Heidelberg Pharma AG reports positive results for ATAC candidates HDP-101 and HDP-102 in Q1 2025, extends cash reach through financing activities, and progresses towards market approval for TLX250-CDx

HDP-101 Heidelberg Pharma AG TLX250-CDx ATAC Candidates HDP-102
BRIEF

published on 03/26/2025 at 09:28, 8 months 10 days ago

Heidelberg Pharma présentera ses innovations ADC à l'AACR 2025

Heidelberg Pharma HDP-201 Technologie ADC AACR 2025 Inhibiteurs De NAMPT
BRIEF

published on 03/26/2025 at 09:28, 8 months 10 days ago

Heidelberg Pharma to Showcase ADC Innovations at AACR 2025

Heidelberg Pharma ADC Technology HDP-201 AACR 2025 NAMPT Inhibitors
PRESS RELEASE

published on 03/26/2025 at 09:23, 8 months 10 days ago

Heidelberg Pharma to Present Data from its ADC Technology Platforms at AACR Annual Meeting 2025
Heidelberg Pharma AG to present latest ADC research results and advancements at AACR Annual Meeting 2025, showcasing Exatecan-based and Amanitin-based ADC technology platforms

Heidelberg Pharma ADC AACR Annual Meeting 2025 Exatecan-based ADC Amanitin-based ADC
BRIEF

published on 03/21/2025 at 07:12, 8 months 15 days ago

Heidelberg Pharma Reports 2024 Financial Results and Clinical Progress

Clinical Trials Heidelberg Pharma ADC Technology Multiple Myeloma 2024 Financial Results
BRIEF

published on 03/21/2025 at 07:12, 8 months 15 days ago

Heidelberg Pharma publie ses résultats financiers et ses progrès cliniques pour 2024

Essais Cliniques Heidelberg Pharma Myélome Multiple Résultats Financiers 2024 Technologie ADC
PRESS RELEASE

published on 03/21/2025 at 07:07, 8 months 15 days ago

Heidelberg Pharma announces financial figures and reports on successful business performance in 2024
Heidelberg Pharma AG reports successful business performance in 2024 with improved financial figures including clinical trial results for HDP-101 in multiple myeloma and upcoming study for HDP-102. Financial outlook and strategy for 2025 highlighted

Financial Results Clinical Trial Heidelberg Pharma AG 2025 Outlook ATAC Technology
BRIEF

published on 03/13/2025 at 07:35, 8 months 23 days ago

Heidelberg Pharma Adjusts Royalty Financing with HealthCare Royalty

FDA Approval Heidelberg Pharma HealthCare Royalty Royalty Financing TLX250-CDx
BRIEF

published on 03/13/2025 at 07:35, 8 months 23 days ago

Heidelberg Pharma ajuste son financement par redevances avec HealthCare Royalty

Heidelberg Pharma Financement Des Redevances Approbation De La FDA TLX250-CDx Redevance Des Soins De Santé
PRESS RELEASE

published on 03/13/2025 at 07:30, 8 months 23 days ago

Heidelberg Pharma Amends Royalty Financing with HealthCare Royalty
Heidelberg Pharma and HealthCare Royalty amend royalty financing agreement, providing for USD 20 million payment and extending cash runway into 2027

Amendment Heidelberg Pharma HealthCare Royalty Royalty Financing Cash Runway

Accesswire

Published on 12/05/2025 at 02:35, 8 hours 50 minutes ago

Future Fuels Initates Drill Permitting at Hornby; Marketing Update
Published on 12/05/2025 at 02:30, 8 hours 55 minutes ago

Klondike Gold Announces AGM Results
Published on 12/05/2025 at 01:00, 10 hours 25 minutes ago

BEACN Closes First Tranche of Non-Brokered Private Placement
Published on 12/04/2025 at 23:05, 12 hours 20 minutes ago

BlackBerry to Announce Third Quarter Fiscal Year 2026 Results on December 18, 2025
Published on 12/04/2025 at 23:00, 12 hours 25 minutes ago

NXT Energy Solutions Completes Data Acquisition for SFD Survey

View all ACCESSWIRE

EQS Group

Published on 12/05/2025 at 11:14, 11 minutes ago

Halfords Group PLC: Director/PDMR Shareholding
Published on 12/05/2025 at 11:08, 16 minutes ago

Linedata Services: Information mensuelle relative au nombre total de droits de vote et d'actions composant le capital social
Published on 12/05/2025 at 10:30, 55 minutes ago

Tradegate Exchange and Börse Berlin merge to form Tradegate BSX
Published on 12/05/2025 at 10:15, 1 hour 10 minutes ago

Wuxi’s Liangxi District: Where 3,000 Years of Jiangnan Culture Thrives
Published on 12/05/2025 at 09:40, 1 hour 45 minutes ago

Chery Partners with 2025 Asian Youth Para Games, Taking Center Stage in Global Sports with Passion and Aspiration

Les Echos

Published on 12/05/2025 at 08:45, 2 hours 40 minutes ago

Air Liquide va étendre et électrifier son unité de production d'oxygène à Shaanxi, soutenant ainsi l'engagement de la Chine à décarboner son industrie
Published on 12/05/2025 at 08:45, 2 hours 40 minutes ago

Air Liquide to expand and electrify its oxygen facility in Shaanxi, supporting China’s commitment to decarbonize its industry
Published on 12/05/2025 at 08:42, 2 hours 43 minutes ago

ENGIE - déclaration mensuelle du nombre total d'actions et de droits de vote composant le capital au 30 novembre 2025
Published on 12/04/2025 at 18:14, 17 hours 10 minutes ago

Résiliation d'une convention conclue entre actionnaires
Published on 12/04/2025 at 18:00, 17 hours 25 minutes ago

Informations relatives au nombre total de droits de vote et d’actions composant le capital social au 28 novembre 2025

View all LES ECHOS COMFI WIRE